Xentria Your Essential Partner for Effective Meitheal

Xentria and Meitheal Pharmaceuticals announce exclusive licensing agreement for XTMAB-16 in North America. Meitheal Pharmaceuticals logo. Who ... Xentria and Meitheal Pharmaceuticals announce exclusive licensing agreement for XTMAB-16 in North America ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Xentria landed a nearly $700 million licensing agreement with Meitheal Pharmaceuticals, a local drugmaker that spun out Xentria in 2020. Xentria is a biologics development company working closely with Meitheal Pharmaceuticals (Chicago, IL),. NKF Pharma (Nanking, China), and KinBio (Rehovot, ... Xentria has entered a licensing agreement with Meitheal Pharmaceuticals to market XTMAB-16 for pulmonary sarcoidosis in North America. Xentria is a biologics development company working closely with Meitheal Pharmaceuticals (Chicago, IL), NKF Pharma (Nanking, China), and KinBio (Rehovot, Israel) ... Xentria's Multi-Year Licensing Agreement with Meitheal. By Martina Bellini. Perkins Coie advised Xentria Inc. on the deal. Xentria Inc., a clinical-stage ... ... Meitheal Pharmaceuticals was the largest, rare disease focused deal in June. Meitheal gained exclusive rights to commercialize Xentria's ... ... Meitheal Pharmaceuticals, Inc.（以下简称“Meitheal”“被许可方”）拟与Xentria签署《许可、开发与商业化协议》（以下简称《许可协议》），Xentria授予 ...